Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations

Limited sensitivity of existing assays has prevented investigation of whether Adriamycin–DNA adducts are involved in the anti-tumour potential of Adriamycin. Previous detection has achieved a sensitivity of a few Adriamycin–DNA adducts/10(4) bp DNA, but has required the use of supra-clinical drug co...

Descripción completa

Detalles Bibliográficos
Autores principales: Coldwell, Kate E., Cutts, Suzanne M., Ognibene, Ted J., Henderson, Paul T., Phillips, Don R.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Methods Online
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532723/
https://www.ncbi.nlm.nih.gov/pubmed/18632763
http://dx.doi.org/10.1093/nar/gkn439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532723/
https://www.ncbi.nlm.nih.gov/pubmed/18632763
http://dx.doi.org/10.1093/nar/gkn439

Ejemplares similares